Johnson & Johnson Company Profile (NYSE:JNJ)

Johnson & Johnson trades on the New York Stock Exchange (NYSE) under the ticker symbol "JNJ."

Johnson & Johnson declared a quarterly dividend on Monday, July 17th. Shareholders of record on Tuesday, August 29th will be given a dividend of $0.84 per share on Tuesday, September 12th. This represents a $3.36 dividend on an annualized basis and a yield of 2.52%. The ex-dividend date is Friday, August 25th. View Johnson & Johnson's Dividend History.

Johnson & Johnson (NYSE:JNJ) issued its earnings results on Tuesday, July, 18th. The company reported $1.83 EPS for the quarter, beating analysts' consensus estimates of $1.79 by $0.04. The company had revenue of $18.84 billion for the quarter, compared to analyst estimates of $18.94 billion. Johnson & Johnson had a net margin of 22.52% and a return on equity of 26.76%. The firm's quarterly revenue was up 1.9% on a year-over-year basis. During the same quarter in the prior year, the business posted $1.74 earnings per share. View Johnson & Johnson's Earnings History.

Johnson & Johnson is scheduled to release their next quarterly earnings announcement on Tuesday, October, 17th 2017. View Earnings Estimates for Johnson & Johnson.

Johnson & Johnson issued an update on its FY17 earnings guidance on Tuesday, July, 18th. The company provided earnings per share (EPS) guidance of $7.12-7.22 for the period, compared to the Thomson Reuters consensus EPS estimate of $7.11. The company issued revenue guidance of $75.8-76.1 billion, compared to the consensus revenue estimate of $75.65 billion.

18 equities research analysts have issued 12-month target prices for Johnson & Johnson's stock. Their predictions range from $110.00 to $148.00. On average, they expect Johnson & Johnson's share price to reach $132.00 in the next twelve months. View Analyst Ratings for Johnson & Johnson.

Here are some recent quotes from research analysts about Johnson & Johnson stock:

• 1. According to Zacks Investment Research, "J&J reported mixed Q2 results, beating on earnings but missing on sales. Sales in J&J’s domestic Pharma segment have decelerated this year as a number of key growth drivers like Remicade and Concerta are facing competition. However, J&J is optimistic that sales growth will accelerate in 2H17. We believe that new products including Xarelto, Stelara, Darzalex, and Imbruvica remain the key to growth.  Meanwhile, share buybacks and the restructuring initiative should provide bottom-line support. J&J is also making rapid progress with its pipeline and line extensions. The Actelion buy adds an attractive new therapeutic area – PAH. J&J’s shares have outperformed the large-cap pharma industry this year so far. However, headwinds like negative currency movement, generics, pricing pressure and soft global market conditions remain. Sluggish growth in the Consumer segment due to category slowdown is also a concern." (7/31/2017)
• 2. BTIG Research analysts commented, "Yesterday, we attended JNJ’s Pharma day held in New Brunswick, NJ. The overarching theme of the day was the expectation that the Pharma business outgrows the IMS projected ~5% 5-year CAGR for branded drugs. Our model is significantly below such expectations, as we have reported growth of ~6.5% during 2017 falling to ~3.6% in 2018 and essentially flat through 2020. Our numbers may prove conservative given that we do not currently include new drug launches of esketamine, guselkumab and sirukumab. We remain Neutral, as we think that the Oncology landscape is becoming more complicated and the Immunology portfolio may underperform internal expectations as a new class of oral drugs comes to market." (5/21/2017)
• 3. UBS AG analysts commented, "After making appropriate adjustments for year-over-year shipping day differences, JNJ's Q4 sales were up an impressive 9.5% in the U.S., and up 7.6% CC WW. Initial 2017 outlook calls for sales of $74.1-74.8 bil (up 4-5% CC) and EPS of $6.93-7.08 (including the AMO deal). As previewed, the guided range reflects greater impact from FX, and by our estimation a degree of conservatism. Given the continued strong growth of key Pharma franchises, management's potential to drive stable to improving margins, the ~$2.5 bil remaining repurchase authorization and other factors, we see flex and potential upside to management's initial 2017 outlook. We reiterate our Buy rating on top large-cap diversified pick JNJ, trimming our target from $142 to $141 due primarily to the ~$4.3 bil cash outlay for AMO, expected to close in 1Q17." (1/25/2017)
• 4. Jefferies Group LLC analysts commented, "With biosimilars and generics expected to drag the next few years, we expect JNJ will continue look to M&A to augment growth. Whilst this should ultimately drive better growth, we believe that investors will not reward the shares for this initially." (1/5/2017)

Some companies that are related to Johnson & Johnson include Pfizer (PFE), Novartis AG (NVS), Merck & Company (MRK), Sanofi (SNY), Novo Nordisk A/S (NVO), GlaxoSmithKline PLC (GSK), Bristol-Myers Squibb Company (BMY), Abbott Laboratories (ABT), Eli Lilly and Company (LLY), Astrazeneca PLC (AZN), GlaxoSmithKline plc (GSK), AstraZeneca plc (AZN), Shire PLC (SHP), Teva Pharmaceutical Industries Limited (TEVA), Patheon NV (PTHN), Dr. Reddy's Laboratories Ltd (RDY), Valeant Pharmaceuticals International (VRX) and Catalent (CTLT).

Johnson & Johnson's management team includes the folowing people:

• Alex Gorsky, Chairman of the Board, Chief Executive Officer
• Dominic J. Caruso, Chief Financial Officer, Executive Vice President
• Peter M. Fasolo Ph.D., Chief Human Resource Officer, Executive Vice President
• Paulus A. Stoffels, Executive Vice President, Chief Scientific Officer
• Michael H. Ullmann, Executive Vice President, General Counsel
• Joaquin Duato, Executive Vice President, Worldwide Chairman - Pharmaceuticals
• Jorge S. Mesquita, Executive Vice President, Worldwide Chairman - Consumer
• Sandra E. Peterson, Executive Vice President - Group Worldwide Chairman
• Joseph Wolk, Vice President - Investor Relations
• Anne M. Mulcahy, Lead Independent Director

Johnson & Johnson's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (7.47%), BlackRock Inc. (6.46%), State Street Corp (5.87%), State Farm Mutual Automobile Insurance Co. (1.41%), Bank of New York Mellon Corp (1.35%) and Northern Trust Corp (1.28%). Company insiders that own Johnson & Johnson stock include Charles Prince, Dominic J Caruso, Gary J Pruden, Paulus Stoffels, Peter Fasolo and Ronald A Kapusta. View Institutional Ownership Trends for Johnson & Johnson.

Johnson & Johnson's stock was sold by a variety of institutional investors in the last quarter, including State Street Corp, Boston Partners, Karp Capital Management Corp, Nordea Investment Management AB, APG Asset Management N.V., Renaissance Technologies LLC, Bank of New York Mellon Corp and Robeco Institutional Asset Management B.V.. Company insiders that have sold Johnson & Johnson stock in the last year include Dominic J Caruso and Paulus Stoffels. View Insider Buying and Selling for Johnson & Johnson.

Johnson & Johnson's stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Janus Henderson Group PLC, Vanguard Group Inc., Parametric Portfolio Associates LLC, Harbour Capital Advisors LLC, FMR LLC, Schroder Investment Management Group and Principal Financial Group Inc.. View Insider Buying and Selling for Johnson & Johnson.

Shares of Johnson & Johnson can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Johnson & Johnson stock can currently be purchased for approximately $133.45.